Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
HRQoL
NET
PRRT
quality of life
Journal
Journal of neuroendocrinology
ISSN: 1365-2826
Titre abrégé: J Neuroendocrinol
Pays: United States
ID NLM: 8913461
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
04
09
2023
received:
14
10
2022
accepted:
18
09
2023
medline:
2
11
2023
pubmed:
9
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health-related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging progression-free survival. The aim of this study was to assess the patient's perspective regarding changes in their HRQoL during PRRT. HRQoL was assessed using the questionnaires for cancer in general, EORTC QLQ-C30, and the gastrointestinal NET-specifically EORTC QLQ-GINET21. Patients with NET (n = 204) rated their HRQoL before PRRT cycles one and four. The medical records of patients were reviewed and their HRQoL was compared to a matched reference population (n = 4910). HRQoL was found to improve during PRRT in aspects of global quality of life; role, social, and emotional functioning, and multiple symptom relief. Potential risk groups for worse HRQoL during PRRT were patients with overweight (BMI >25) who completed four cycles of PRRT and older patients (>65 years old). In conclusion, we found that PRRT improves HRQoL in patients with NETs. The results of this study may be used to improve person-centred care.
Substances chimiques
Radioisotopes
0
Receptors, Peptide
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13342Informations de copyright
© 2023 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
Références
Boyar Cetinkaya R, Aagnes B, Myklebust T, Thiis-Evensen E. Survival in neuroendocrine neoplasms: a report from a large Norwegian population-based study. Intnational Journal of Cancer. 2018;142:1139-1147. doi:10.1002/ijc.31137
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335-1342. doi:10.1001/jamaoncol.2017.0589
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68:471-487. doi:10.3322/caac.21493
Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713-734. doi:10.1097/MPA.0b013e3181ebaffd
Buscombe JR. Evidence base for the use of PRRT. Sem Nucl Med. 2020;50:399-404. doi:10.1053/j.semnuclmed.2020.04.001
Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. Current Oncoogyl Reports. 2017;19:9. doi:10.1007/s11912-017-0567-8
Gosain R, Gupta M, Ray AM, Strosberg J, Glaser KM, Iyer R. Health-related quality of life (HRQoL) in neuroendocrine Tumours: a systemic review. Cancer. 2022;14:1428. doi:10.3390/cancers14061428
Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surg Oncol Clin N Am. 2018;27:675-684. doi:10.1016/j.soc.2018.05.008
Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Global Oncol. 2017;3:43-53. doi:10.1200/jgo.2015.002980
Milanetto AC, Nordenström E, Sundlöv A, Almquist M. Health-related quality of life after surgery for small intestinal neuroendocrine Tumours. World J Surg. 2018;42:3231-3239. doi:10.1007/s00268-018-4638-2
Marinova M, Mucke M, Fischer F, et al. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2019;46:2252-2259. doi:10.1007/s00259-019-04431-3
Marinova M, Mucke M, Mahlberg L, et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging. 2018;45:38-46. doi:10.1007/s00259-017-3816-z
Martini C, Buxbaum S, Rodrigues M, et al. Quality of life in patients with metastatic Gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy: information from a monitoring program in clinical routine. J Nucl Med. 2018;59:1566-1573. doi:10.2967/jnumed.117.204834
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. doi:10.1093/jnci/85.5.365
Jiménez-Fonseca P, Carmona-Bayonas A, Martín-Pérez E, et al. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev. 2015;34:381-400. doi:10.1007/s10555-015-9573-1
Yadegarfar G, Friend L, Jones L, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108:301-310. doi:10.1038/bjc.2012.560
Derogar M, van der Schaaf M, Lagergren P. Reference values for the EORTC QLQ-C30 quality of life questionnaire in a random sample of the Swedish population. Acta Oncol. 2012;51:10-16. doi:10.3109/0284186x.2011.614636
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual Edn 3, Brussels. European Organisation for Research and Treatment of Cancer. European Organisation for Research and Treatment of Cancer; 2001.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144. doi:10.1200/jco.1998.16.1.139
Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52:1361-1368. doi:10.2967/jnumed.111.087932
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578-2584. doi:10.1200/jco.2018.78.5865
Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev. 2001;2:219-229. doi:10.1046/j.1467-789x.2001.00040.x